Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BioNxt Solutions Inc. (BNXTF : OTC)
 
 • Company Description   
BioNxt Solutions Inc. is a bioscience accelerator focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations. BioNxt Solutions Inc., formerly known as XPhyto Therapeutics Corp., is based in VANCOUVER, BC.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.39 Daily Weekly Monthly
20 Day Moving Average: 2,250 shares
Shares Outstanding: 115.76 (millions)
Market Capitalization: $45.60 (millions)
Beta: 0.77
52 Week High: $0.44
52 Week Low: $0.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.05% -3.79%
12 Week 11.05% -6.59%
Year To Date 56.37% 46.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1820 Fir Street Suite 270
-
Vancouver,BC V6J 3B1
CAN
ph: 780-818-6422
fax: -
None https://bionxt.com
 
 • General Corporate Information   
Officers
Hugh Rogers - Chief Executive Officer
Joseph Meagher - Chief Financial Officer
Roland Spleiss - Director
Raimar Lobenberg - Director
Wolfgang Probst - Director

Peer Information
BioNxt Solutions Inc. (GSAC)
BioNxt Solutions Inc. (CASI)
BioNxt Solutions Inc. (ALCD.)
BioNxt Solutions Inc. (OMNN)
BioNxt Solutions Inc. (CGPI.)
BioNxt Solutions Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 090974106
SIC: -
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/27/25
Share - Related Items
Shares Outstanding: 115.76
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $45.60 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/27/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 2,279.93
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -78.57%
vs. Previous Quarter: -76.92%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -616.01
12/31/24 - -606.17
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -19,165.00
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -19,165.00
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©